10 Posts Not To Miss From EHA 2026

EHA 2026 in Stockholm brought together thousands of hematologists, researchers, and healthcare professionals to share the latest advances shaping the future of hematology.

Non-malignant hematology was a major focus, with new data and clinical insights in thrombosis, hemostasis, sickle cell disease, hemophilia and other bleeding and clotting disorders.

Beyond the scientific program, the meeting also sparked active discussion across social media, where experts shared key findings, highlighted important presentations and reflected on clinical implications.

Below are 10 standout posts from EHA 2026 capturing key updates and conversations from the meeting.

Cornelia Englisch, Resident at Hanusch Hospital:

“I am honored and grateful for the opportunity to speak at the European Hematology Association (EHA) Congress 2026 on one of my favorite topics: clonal hematopoiesis and thrombosis risk.

Many thanks to the organizers for the invitation and the opportunity to contribute.

Fittingly, we recently published a forum article in RPTH Journal highlights key knowledge gaps in our understanding of the relationship between clonal hematopoiesis and thrombosis risk.”

Sarah Hendry, Franchise Head, Hematology/Oncology at Spherix Global Insights:

“Pumped to be starting a packed day 2 at hashtag EHA 2026 with Samuel Young and Spherix Global Insights!

We have a poster presentation looking at gene therapy uptake dynamics in hemophilia and hemoglobinopathies tonight in poster hall A – hope to see you there!”

Amber Yates, Senior Medical Director and Global Medical Affairs Leader at Agios Pharmaceuticals:

“Reflecting on Day 3 at EHA 2026.

Today, we shared the RISE UP results from Agios.

Five years ago, I made the decision to step away from academic medicine.

It wasn’t easy, because caring directly for patients with Sickle Cell shaped so much of who I was as a physician.

But I left with a very clear purpose: to find a way to impact more lives, at a broader scale, than I could one patient at a time.

Sitting with my colleagues today and seeing these data being shared with the hematology community, fills me with pride for the Sickle Cell community—patients and families who showed up, trusted the process, and participated in RISE UP—this progress is only possible through their courage and commitment.

Grateful to be part of a community that continues to show up and keep patients at the center of everything we do.

A thousand thanks to Ahmar U. Zaidi, who is the shining light of encouragement at Agios.”

Zoe Billinghurst, Senior Global Brand Director of Rare Blood and Renal Disorders at Novo Nordisk:

“Building insights about Rare Blood Disorders – global unmet needs, clinical practice, research advances – steps forward since EHA 2025.

Building on established collaborations and instigating new ones. Amazing and intense week in Stockholm at EHA 2026 with amazing colleagues from Novo Nordisk Rare Disease team.”

Christina Ornauer, Vice President, Head of Medical Affairs of Hematology Europe at Avanzanite Bioscience:

“Attending EHA 2026 was truly inspiring, as I connected with dedicated colleagues, researchers, and healthcare professionals focused on advancing patient care.

The congress showcased the remarkable pace of innovation in hematology and emphasized the importance of collaboration within the healthcare community.

I am grateful for the opportunity to learn, exchange perspectives, and bring new insights back to my work.

Thank you to everyone who shared their expertise and passion throughout the meeting.

I look forward to seeing how these advances continue to shape the future for patients.”

Omid Seidizadeh, Research Leader of the A. Bianchi Bonomi Hemophilia and Thrombosis Center:

“Honored to be invited to speak at European Hematology Association (EHA) 2026 in the session ‘Von Willebrand Disease: Time for Every Hematologist to Know’.

I will be presenting ‘From Common to Complex: Understanding VWD’ and look forward to sharing insights and discussing advances in von Willebrand disease with colleagues from around the world.”

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital:

“Base editing. Gene editing 2.0?

At EHA 2026, Maria Morelló Miravet (Karolinska Institutet, Stockholm) showed how precise base editing of hematopoietic stem cells (HSCs) can move from concept to clinic in sickle cell disease (SCD):

Unlike classical CRISPR‑Cas9 nucleases that rely on double‑strand breaks and stochastic indels, base editors convert single nucleotides at predefined sites using deaminases fused to a Cas9 nickase.

This enables highly controlled editing of regulatory elements such as HBG promoters or BCL11A‑related loci, with the goal of re‑inducing fetal hemoglobin (HbF) while limiting chromosomal rearrangements and p53‑mediated stress responses.

This presentation is a powerful reminder that academia can drive first‑in‑class, highly sophisticated innovative programs, from basic biology and manufacturing to regulatory strategy and clinical implementation.”

Ruben Mesa, President of Cancer National Service Line at Advocate Health:

“EHA 2026 glad to have been a coinvestigator on Independence showing anemia benefit with Luspatercept in MF Anemia with positive trend for the intervention, with potential confounders from differences in international transfusion practices.”

Alfadil Haroon, Assistant Consultant of Hematology at King Faisal Specialist Hospital and Research Centre, Assistant Professor at Alfaisal University:

“Decoding the complexity of factor II deficiency: new insights from EHA 2026

Factor II (prothrombin) deficiency is rare, but its clinical impact is profound. Our latest retrospective analysis of 106 patients reveals critical distinctions between congenital and acquired forms:

• Acquired FII Deficiency: Often presents later (median age 34) and is highly associated with autoimmune diseases and malignancy. Notably, 30.8% of these patients experience thrombotic events -strongly linked to autoimmune comorbidities (OR 5.43).
• Congenital FII Deficiency: Typically diagnosed much earlier (median age 16) with a significantly higher lifetime bleeding burden. Interestingly, we found no strong correlation between FII activity levels and bleeding severity, highlighting the need for individualized clinical assessment over lab values alone.

These findings underscore that Factor II deficiency isn’t just a bleeding disorder -it’s a complex balancing act between hemorrhage and thrombosis.”

Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center:

“Aplastic Anemia in 2026: Moving Beyond Traditional IST

The management of severe aplastic anemia continues to evolve.

While horse ATG plus cyclosporine remains the backbone of frontline immunosuppressive therapy, recent studies and EHA 2026 discussions highlight the growing role of thrombopoietin receptor agonists (especially eltrombopag) in improving hematologic responses and reducing transfusion dependence.

Key trends shaping 2026 practice include:

Earlier integration of TPO-receptor agonists into frontline therapy

Improved risk stratification through molecular profiling and clonal evolution monitoring

More individualized treatment selection based on age, donor availability, and genomic findings

Ongoing refinement of the balance between immunosuppression and stem cell transplantation strategies

The future of aplastic anemia treatment is increasingly focused on precision medicine, deeper responses, and long-term prevention of clonal progression.”

Read more posts from EHA 2026 on Hemostasis Today.